These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 15031735)

  • 1. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
    Matthews T; Salgo M; Greenberg M; Chung J; DeMasi R; Bolognesi D
    Nat Rev Drug Discov; 2004 Mar; 3(3):215-25. PubMed ID: 15031735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV entry inhibitors: a new generation of antiretroviral drugs.
    Krambovitis E; Porichis F; Spandidos DA
    Acta Pharmacol Sin; 2005 Oct; 26(10):1165-73. PubMed ID: 16174430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.
    Soria A; Cavarelli M; Sala S; Alessandrini AI; Scarlatti G; Lazzarin A; Castagna A
    J Med Virol; 2008 Jun; 80(6):937-41. PubMed ID: 18428138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
    Cooper DA; Lange JM
    Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entry inhibitors in the treatment of HIV-1 infection.
    Tilton JC; Doms RW
    Antiviral Res; 2010 Jan; 85(1):91-100. PubMed ID: 19683546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 9. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
    Fung HB; Guo Y
    Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Katy, bar the door! HIV entry inhibitors.
    Martinez LJ
    Res Initiat Treat Action; 2000 Jun; 6(2):6-12. PubMed ID: 11707878
    [No Abstract]   [Full Text] [Related]  

  • 17. Enfuvirtide: from basic investigations to current clinical use.
    Joly V; Jidar K; Tatay M; Yeni P
    Expert Opin Pharmacother; 2010 Nov; 11(16):2701-13. PubMed ID: 20977403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV fusion and its inhibition in antiretroviral therapy.
    Greenberg M; Cammack N; Salgo M; Smiley L
    Rev Med Virol; 2004; 14(5):321-37. PubMed ID: 15334539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enfuvirtide.
    Lalezari JP; Luber AD
    Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.